Decoding t(5;12)(q31;p13): What Does This Rare Genetic Translocation Mean for Leukemia?
"Exploring the role of the t(5;12)(q31;p13) translocation in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and acute eosinophilic leukemia (AEL)."
In the realm of cancer genetics, specific chromosomal abnormalities can provide critical insights into the development and progression of the disease. One such abnormality, the t(5;12)(q31;p13) translocation, involves the swapping of genetic material between chromosomes 5 and 12. This rare event has been linked to certain types of blood cancers, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and acute eosinophilic leukemia (AEL).
This article delves into the intricacies of the t(5;12)(q31;p13) translocation, exploring its genetic underpinnings, associated clinical features, and potential implications for diagnosis and treatment. Understanding this translocation can provide valuable insights into the complex landscape of leukemia and related disorders.
Originally published in the Atlas of Genetics and Cytogenetics in Oncology and Haematology in March 2007, this review compiles the existing knowledge surrounding this specific genetic anomaly. While medical research has progressed since then, the foundational information remains relevant for understanding the role of t(5;12)(q31;p13) in specific leukemias.
Clinical Diversity and Diagnostic Complexity
The t(5;12)(q31;p13) is a recurrent but rare translocation that forms the ETV6::ACSL6 fusion gene. It occurs across myeloid malignancies, with a slight predominance of chronic myeloid disorders, typically chronic eosinophilic leukemia not otherwise specified. A 2026 report described chronic myeloid neoplasms in six of seven patients and acute myeloid leukemia (AML) in one. The translocation was the sole abnormality in four cases, while three had complex karyotypes with at least three aberrations, including a TP53 deletion.
Early Recognition of ETV6 and ACSL6 Involvement
The t(5;12)(q31;p13) was identified as involving ETV6 at 12p13 and ACSL6 at 5q31. An early report described the translocation in a patient with refractory anemia with excess blasts (RAEB) and basophilia, a patient with AML and eosinophilia, and a patient with acute eosinophilic leukemia. Later analysis of seven cases found chronic myeloid neoplasms in six patients and AML in one. In four of those cases, the translocation was the sole abnormality, whereas three had complex karyotypes that included TP53 deletion.
Unpacking the Basics: What is t(5;12)(q31;p13)?
The t(5;12)(q31;p13) designation describes a translocation, a type of chromosomal abnormality where parts of two chromosomes break off and reattach to each other. In this specific case, the translocation occurs between chromosome 5 and chromosome 12. The (q31) and (p13) refer to the specific locations on these chromosomes where the breaks occur: q31 is a region on the long arm (q) of chromosome 5, and p13 is a region on the short arm (p) of chromosome 12.
- ETV6 (ETS Variant Gene 6): Located on chromosome 12 at position 12p13, ETV6 is a transcription factor involved in regulating the development of blood cells. It is known to participate in many chromosomal rearrangements associated with leukemia and congenital fibrosarcoma.
- ACSL6 (Acyl-CoA Synthetase Long-chain Family Member 6): Located on chromosome 5 at position 5q31, ACSL6 plays a crucial role in fatty acid metabolism, particularly in the brain and red blood cells.
A Rare Recurrent Myeloid Abnormality
Reviews describe t(5;12)(q31;p13) as a recurrent mutation associated with several myeloid disorders. Reported settings include refractory anemia with excess blasts (RAEBt) with basophilia, AML with eosinophilia, and acute eosinophilic leukemia. The translocation is therefore linked to more than one leukemia or myeloid disease category rather than a single uniform presentation. An Atlas of Genetics and Cytogenetics in Oncology and Haematology entry specifically covers t(5;12)(q31;p13) in MDS, AML, and AEL.
A p53-Related Comparison Point
A separate study examined HLA-B-associated transcript 3, also called Bat3 or Scythe, in the control of p53 acetylation. It reported that Bat3/Scythe has an essential role in p300-mediated acetylation of p53. This function is required for DNA damage responses. The finding provides a p53-centered molecular comparison point, but the cited source does not establish that Bat3/Scythe is part of t(5;12)(q31;p13).
The Future of Research on t(5;12)(q31;p13)
While the original research provides a solid foundation, continued investigation into the t(5;12)(q31;p13) translocation is essential. Future studies should focus on: identifying new therapeutic targets based on the ETV6/ACSL6 fusion protein, developing more sensitive diagnostic tools to detect the translocation early on, and conducting clinical trials to evaluate the effectiveness of targeted therapies in patients with t(5;12)(q31;p13)-positive leukemias. Ultimately, a deeper understanding of this rare genetic event will pave the way for more personalized and effective treatments for patients with these challenging blood cancers.
Avoiding Confusion Between Similar Translocations
Future interpretation of t(5;12) findings requires careful attention to the breakpoint designation. The t(5;12)(q33;p13) involving ETV6 and PDGFRB must not be confused with t(5;12)(q31;p13). The cited source notes that the q31;p13 translocation was found in an acute lymphoblastic leukemia (ALL) cell line with IL3 and ETV6 involvements. Thus, similar chromosome-number pairings can represent biologically distinct rearrangements.
Separating q33;p13 From q31;p13
A broader leukemia context includes t(5;12)(q33;p13), which produces an ETV6/PDGFRB gene fusion. The cited Blood article describes this rearrangement as a recurrent chromosomal abnormality associated with chronic myelomonocytic leukemia (CMML). This q33;p13 abnormality is distinct from the q31;p13 translocation discussed elsewhere in this article. Keeping these breakpoint coordinates separate is essential when comparing leukemia subtypes and gene fusions.